万达生物制药(VNDA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VNDA 万达生物制药

交易中 05-06 15:39:51 EDT

7.44

+0.05

+0.61%

最高7.74	最低7.42	成交量134.37万
今开7.50	昨收7.39	日振幅4.33%
总市值4.47亿	流通市值4.03亿	总股本6,014万
成交额1,017万	换手率2.48%	流通股本5,420万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"VNDA","market":"US","secType":"STK","nameCN":"万达生物制药","latestPrice":7.435,"timestamp":1778096389080,"preClose":7.39,"halted":0,"volume":1343671,"delay":0,"changeRate":0.006089309878213793,"floatShares":54199300,"shares":60135062,"eps":-3.741276,"marketStatus":"交易中","change":0.045,"latestTime":"05-06 15:39:51 EDT","open":7.5,"high":7.735,"low":7.415,"amount":10167158.043042,"amplitude":0.043302,"askPrice":7.44,"askSize":414,"bidPrice":7.43,"bidSize":1088,"shortable":3,"etf":0,"ttmEps":-3.741276,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1778097600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1144814400000,"exchange":"NASDAQ","adjPreClose":7.39,"preHourTrading":{"tag":"盘前","latestPrice":7.5,"preClose":7.39,"latestTime":"09:14 EDT","volume":6488,"amount":48446.171091200005,"timestamp":1778073296680,"change":0.11,"changeRate":0.014885,"amplitude":0.032476},"postHourTrading":{"tag":"盘后","latestPrice":7.4643,"preClose":7.39,"latestTime":"19:56 EDT","volume":14006,"amount":104727.5724,"timestamp":1778025361673,"change":0.0743,"changeRate":0.010054,"amplitude":0.021069},"volumeRatio":1.276144,"impliedVol":0.5309,"impliedVolPercentile":0.3745},"requestUrl":"/m/hq/s/VNDA","defaultTab":"news","newsList":[{"id":"1172511226","title":"万达生物制药宣布Nereus™（Tradipitant）在美国上市，系40余年来首款晕动症新药","url":"https://stock-news.laohu8.com/highlight/detail?id=1172511226","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172511226?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:03","pubTimestamp":1777896224,"startTime":"0","endTime":"0","summary":"万达生物制药近日宣布，其研发的Nereus™（Tradipitant）已正式在美国市场投入商业销售。该药物成为四十多年来首款针对晕动症患者的新型药理治疗方案，标志着晕动症治疗领域迎来重大突破。\n此次上市意味着长期受晕动症困扰的患者将获得全新的治疗选择。Nereus™的推出不仅填补了该领域数十年的技术空白，更展现了医药创新对提升人类生活质量的持续推动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VNDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116493607","title":"万达生物制药：持有效处方患者可获Nereus药物 现金支付价为每剂85美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1116493607","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116493607?lang=zh_cn&edition=full","pubTime":"2026-05-02 04:38","pubTimestamp":1777667891,"startTime":"0","endTime":"0","summary":"万达生物制药宣布，持有合规处方的患者现可通过现金支付方式获取Nereus药物，单剂定价为85美元。该方案为患者提供了直接购买渠道，无需经过传统保险报销流程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VNDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140245743","title":"万达生物制药宣布Nereus™（Tradipitant）在美国上市，系四十余年来首款晕动症新药","url":"https://stock-news.laohu8.com/highlight/detail?id=1140245743","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140245743?lang=zh_cn&edition=full","pubTime":"2026-05-02 04:37","pubTimestamp":1777667841,"startTime":"0","endTime":"0","summary":"美国医药市场迎来突破性进展——万达生物制药旗下新型晕动症治疗药物Nereus正式启动商业销售。这款神经激肽-1受体拮抗剂成为四十多年来首个针对晕动症的创新药理疗法，标志着该领域治疗空白终被填补。临床研究显示，口服Nereus能有效阻断引发恶心呕吐的关键神经信号通路。值得注意的是，该药物曾于2023年完成三期临床试验，数据显示用药组晕动症状发生率降低超70%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154480528","title":"万达生物制药敦促FDA撤回2027财年立法议程中延长药物审评时限的提案","url":"https://stock-news.laohu8.com/highlight/detail?id=1154480528","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154480528?lang=zh_cn&edition=full","pubTime":"2026-04-09 23:04","pubTimestamp":1775747053,"startTime":"0","endTime":"0","summary":"万达生物制药（Vanda Pharmaceuticals）近日呼吁美国食品药品监督管理局（FDA）从其2027财年立法议程中撤销一项旨在延长药物审评时间表的提案。该公司认为，此举可能对药物研发进程产生不利影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VNDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118743082","title":"万达生物制药启动Thetis研究：评估Nereus™预防GLP-1受体激动剂所致呕吐的临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1118743082","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118743082?lang=zh_cn&edition=full","pubTime":"2026-04-09 04:46","pubTimestamp":1775681177,"startTime":"0","endTime":"0","summary":"万达生物制药宣布正式启动名为\"Thetis研究\"的临床试验，该试验旨在评估其创新药物Nereus对GLP-1受体激动剂引发的呕吐症状的预防效果。这项研究将针对使用GLP-1受体激动剂治疗时出现胃肠道不良反应的患者群体，探索Nereus在控制药物相关性呕吐方面的潜在疗效。若试验结果积极，Nereus有望成为首款专门针对GLP-1类药物相关呕吐症状的预防性疗法，为全球数百万相关患者提供新的解决方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146656831","title":"欧洲药品管理局人用药品委员会：确认拒绝Hetlioz（塔西美尔通）营销授权变更的建议","url":"https://stock-news.laohu8.com/highlight/detail?id=1146656831","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146656831?lang=zh_cn&edition=full","pubTime":"2026-03-27 19:45","pubTimestamp":1774611912,"startTime":"0","endTime":"0","summary":"欧洲药品管理局人用药品委员会（CHMP）已确认其建议，拒绝批准对Hetlioz（塔西美尔通）营销授权的变更申请。该决定维持了委员会早前的立场，意味着相关制药公司——万达生物制药（Vanda Pharmaceuticals）——此次申请未获通过。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106740354","title":"万达生物制药呼吁FDA加速推动动物试验向人体相关方法转型","url":"https://stock-news.laohu8.com/highlight/detail?id=1106740354","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106740354?lang=zh_cn&edition=full","pubTime":"2026-03-20 04:37","pubTimestamp":1773952632,"startTime":"0","endTime":"0","summary":"万达生物制药近日公开敦促美国食品药品监督管理局采取实质性行动，加快医药研发领域从传统动物试验向更具人体相关性的替代方法转变。该公司指出，当前基于人类生物学的新型检测技术已展现出更精准预测药物反应的潜力，此举将有望重构药物安全评估体系，提升临床转化效率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VNDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152286791","title":"欧洲药管局拒绝Hetlioz新增史密斯-马吉利斯综合征成人夜间睡眠障碍适应症的申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1152286791","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152286791?lang=zh_cn&edition=full","pubTime":"2026-03-18 00:17","pubTimestamp":1773764233,"startTime":"0","endTime":"0","summary":"欧洲药品管理局近日正式否决了关于拓展Hetlioz（塔司普雷酮）营销授权的申请，该申请旨在将史密斯-马吉利斯综合征成人患者的夜间睡眠障碍纳入治疗范围。此次决定意味着由万达生物制药开发的这款褪黑素受体激动剂暂无法在欧洲市场扩大其临床适用范围。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618675841","title":"Vanda Pharmaceuticals Inc.盘中异动 大幅上涨5.07%报8.29美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618675841","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618675841?lang=zh_cn&edition=full","pubTime":"2026-03-09 23:33","pubTimestamp":1773070438,"startTime":"0","endTime":"0","summary":"北京时间2026年03月09日23时33分，Vanda Pharmaceuticals Inc.股票出现波动，股价急速拉升5.07%。Vanda Pharmaceuticals Inc.股票所在的生物技术行业中，整体涨幅为0.50%。Vanda Pharmaceuticals Inc.公司简介：万达生物制药有限公司是一家生物制药公司，该公司致力于开发和商业化疗法，以满足大量未满足的医疗需求，并改善患者的生活。大部分收入来自 Fanapt 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030923335897ab39f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030923335897ab39f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VNDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146152400","title":"万达生物制药宣布美国FDA为Hetlioz®时差障碍适应症召开里程碑式听证会，系40余年来首次新药审批听证","url":"https://stock-news.laohu8.com/highlight/detail?id=1146152400","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146152400?lang=zh_cn&edition=full","pubTime":"2026-03-03 21:04","pubTimestamp":1772543085,"startTime":"0","endTime":"0","summary":"万达生物制药宣布，美国食品药品监督管理局已为其药物Hetlioz®用于治疗时差障碍的申请召开了一次具有里程碑意义的听证会。此次听证会是FDA超过40年来首次针对新药审批举行的听证会，标志着监管程序的一个重要突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119330741","title":"EMA人用医药产品委员会：万达生物制药的伊洛哌酮获负面意见 用于精神分裂症治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1119330741","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119330741?lang=zh_cn&edition=full","pubTime":"2026-02-27 18:54","pubTimestamp":1772189699,"startTime":"0","endTime":"0","summary":"欧洲药品管理局人用医药产品委员会对万达生物制药旗下药物伊洛哌酮治疗精神分裂症的申请出具了否定性评估意见。该决定意味着该药物现阶段未获得委员会推荐批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VNDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138725313","title":"万达生物制药盘前股价上涨2.3%，FDA受理其罕见皮肤病药物审查申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1138725313","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138725313?lang=zh_cn&edition=full","pubTime":"2026-02-25 21:39","pubTimestamp":1772026751,"startTime":"0","endTime":"0","summary":"万达生物制药股价在盘前交易中录得2.3%的上涨，此前美国食品药品监督管理局已正式受理该公司针对罕见皮肤病药物的审查申请。这一进展标志着该药物在监管审批流程中迈出了关键一步，为后续可能的市场准入奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130498462","title":"万达生物制药宣布美国FDA受理imsidolimab治疗泛发性脓疱型银屑病的生物制品许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1130498462","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130498462?lang=zh_cn&edition=full","pubTime":"2026-02-25 20:41","pubTimestamp":1772023308,"startTime":"0","endTime":"0","summary":"万达生物制药公司宣布，美国食品药品监督管理局已正式受理其候选药物imsidolimab用于治疗泛发性脓疱型银屑病的生物制品许可申请。\nFDA已为该申请设定了目标审评日期为2026年12月12日。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VNDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177212007","title":"万达生物制药宣布美国FDA受理Imsidolimab治疗泛发性脓疱型银屑病的生物制品许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1177212007","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177212007?lang=zh_cn&edition=full","pubTime":"2026-02-25 20:30","pubTimestamp":1772022603,"startTime":"0","endTime":"0","summary":"万达生物制药近日宣布，其针对泛发性脓疱型银屑病治疗的生物制剂Imsidolimab的生物制品许可申请，已获得美国食品药品监督管理局的正式受理。这一进展标志着该药物向获批上市迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VNDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189163157","title":"万达生物制药更新Bysanti安全警告：老年痴呆相关精神病患者死亡率上升","url":"https://stock-news.laohu8.com/highlight/detail?id=1189163157","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189163157?lang=zh_cn&edition=full","pubTime":"2026-02-21 07:02","pubTimestamp":1771628539,"startTime":"0","endTime":"0","summary":"万达生物制药公司近日对其药物Bysanti的使用说明进行了重要更新，新增了一项安全警告。该警告指出，在患有痴呆相关精神病的老年患者群体中，使用Bysanti可能导致死亡率增加。\n这一更新是基于最新的临床数据和安全性评估结果。公司强调，医疗专业人员在为这类特定患者群体处方Bysanti时，需仔细权衡其获益与潜在风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VNDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107914472","title":"万达生物制药宣布Bysanti™（米沙哌隆）获FDA批准用于治疗双相I型障碍和精神分裂症——新化学实体开启精神科创新新纪元","url":"https://stock-news.laohu8.com/highlight/detail?id=1107914472","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107914472?lang=zh_cn&edition=full","pubTime":"2026-02-21 07:00","pubTimestamp":1771628411,"startTime":"0","endTime":"0","summary":"万达生物制药宣布，其创新药物Bysanti™（米沙哌隆）已获得美国食品药品监督管理局批准，用于治疗双相I型障碍与精神分裂症。作为全新化学实体，该药物的获批标志着精神疾病治疗领域迎来重大突破，为精神病学创新开辟了全新视野。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VNDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172660268","title":"万达生物制药公布年度营收指引：现有商业化产品收入预计达2.3亿至2.6亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1172660268","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172660268?lang=zh_cn&edition=full","pubTime":"2026-02-12 05:03","pubTimestamp":1770843790,"startTime":"0","endTime":"0","summary":"万达生物制药近日发布了针对当前已商业化产品的年度财务展望，公司预计其全年营收将落在2.3亿美元至2.6亿美元的区间内。这一指引反映了公司对其核心产品市场表现的信心与预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VNDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194839696","title":"美国FDA拒绝时差症药物申请，万达生物制药盘前股价重挫近12%","url":"https://stock-news.laohu8.com/highlight/detail?id=1194839696","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194839696?lang=zh_cn&edition=full","pubTime":"2026-01-08 20:38","pubTimestamp":1767875892,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）正式否决了万达生物制药针对时差症治疗药物的上市申请，这一监管挫折直接冲击了市场信心。\n受此消息影响，万达生物制药股价在盘前交易时段应声下挫，跌幅一度接近12%，反映出投资者对公司短期前景的担忧急剧升温。\n此次FDA的拒绝决定意味着该药物在获批道路上遭遇重大障碍，公司可能需要补充更多临床数据或调整申请策略，从而推迟了潜在商业化时间表。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185252065","title":"万达生物制药宣布收到美国食品药品监督管理局关于Hetlioz®时差障碍补充新药申请的决定函","url":"https://stock-news.laohu8.com/highlight/detail?id=1185252065","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185252065?lang=zh_cn&edition=full","pubTime":"2026-01-08 20:10","pubTimestamp":1767874255,"startTime":"0","endTime":"0","summary":"万达生物制药今日宣布，已正式收到美国食品药品监督管理局（FDA）针对其Hetlioz®药物治疗时差障碍的补充新药申请（sNDA）所发出的决定函。\n此次决定函的接收标志着Hetlioz®在拓展适应症方面迈出了关键一步。Hetlioz®是该公司的一款核心产品，此次补充申请旨在将其应用范围延伸至时差障碍的治疗领域。\n公司表示，将仔细评估FDA决定函中的具体内容，并据此确定下一步的研发与申报策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VNDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595670884","title":"美股异动 | 止吐新药Nereus获FDA批准 万达生物制药(VNDA.US)涨超32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595670884","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595670884?lang=zh_cn&edition=full","pubTime":"2025-12-31 23:30","pubTimestamp":1767195022,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周三，万达生物制药股价走高，截至发稿，该股涨超32%，报9.33美元。消息面上，公司表示，其新药Nereus已获得美国食品药品监督管理局批准，该药物可用于预防由运动引发的呕吐。公司称，FDA的批准决定基于三项临床研究结果。数据显示，Nereus在降低呕吐事件方面取得“显著减少”的效果，同时在短期、急性使用场景下展现出“良好的安全性特征”。Vanda表示，计划在未来几个月内正式推出Nereus。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387975.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","VNDA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vandapharma.com","stockEarnings":[{"period":"1week","weight":0.0804},{"period":"1month","weight":0.0557},{"period":"3month","weight":-0.0276},{"period":"6month","weight":0.6757},{"period":"1year","weight":0.61},{"period":"ytd","weight":-0.1621}],"compareEarnings":[{"period":"1week","weight":0.017},{"period":"1month","weight":0.1036},{"period":"3month","weight":0.0548},{"period":"6month","weight":0.0798},{"period":"1year","weight":0.2844},{"period":"ytd","weight":0.0614}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Vanda Pharmaceuticals Inc.于2002年在特拉华州注册成立。该公司是一家全球领先的生物制药公司，专注于创新疗法的开发和商业化，以解决高度未满足的医疗需求并改善患者的生活。该公司努力推进新的方法，通过负责任的创新将重要的新药推向市场。该公司致力于在药物发现、临床试验和产品的商业定位中使用支持健全科学的技术，包括遗传学和基因组学。","yearOnYearQuotes":[{"month":1,"riseRate":0.45,"avgChangeRate":-0.03173},{"month":2,"riseRate":0.5,"avgChangeRate":0.001567},{"month":3,"riseRate":0.4,"avgChangeRate":-0.029111},{"month":4,"riseRate":0.45,"avgChangeRate":-0.010662},{"month":5,"riseRate":0.5,"avgChangeRate":0.729143},{"month":6,"riseRate":0.6,"avgChangeRate":0.048231},{"month":7,"riseRate":0.4,"avgChangeRate":-0.033343},{"month":8,"riseRate":0.45,"avgChangeRate":-0.00253},{"month":9,"riseRate":0.3,"avgChangeRate":-0.047775},{"month":10,"riseRate":0.45,"avgChangeRate":-0.012144},{"month":11,"riseRate":0.65,"avgChangeRate":0.054208},{"month":12,"riseRate":0.55,"avgChangeRate":0.052442}],"exchange":"NASDAQ","name":"万达生物制药","nameEN":"Vanda Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"万达生物制药(VNDA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供万达生物制药(VNDA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"万达生物制药,VNDA,万达生物制药股票,万达生物制药股票老虎,万达生物制药股票老虎国际,万达生物制药行情,万达生物制药股票行情,万达生物制药股价,万达生物制药股市,万达生物制药股票价格,万达生物制药股票交易,万达生物制药股票购买,万达生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"万达生物制药(VNDA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供万达生物制药(VNDA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}